Does immunosuppressive treatment ameliorate morphology changes in encapsulating peritoneal sclerosis?

Area of Science:

• Nephrology
• Gastroenterology
• Immunology

Background:

• Encapsulating peritoneal sclerosis (EPS) is a serious complication of peritoneal dialysis, characterized by peritoneal membrane fibrosis and ileus.
• Current treatment options for EPS lack evidence-based support, necessitating research into novel therapeutic strategies.
• Anti-inflammatory and immunosuppressive (IS) treatments are emerging as potential interventions for EPS management.

Purpose of the Study:

• To evaluate the efficacy of various immunosuppressive (IS) agents, including glucocorticosteroids (GC), azathioprine (AZT), and cyclosporin (CsA), in mitigating EPS progression.
• To assess the impact of these IS therapies on key pathological features of EPS, such as peritoneal thickness, inflammation, vascularity, and fibrosis.

Main Methods:

• A rat model of EPS was induced using chlorhexidine gluconate (CG) and ethanol.
• Rats were divided into groups receiving saline (Control), CG, peritoneal rest, GC (prednisolone), AZT, or CsA.
• Peritoneal morphology was histopathologically assessed after a 3-week treatment period.

Main Results:

• CG induction significantly increased peritoneal thickness, inflammation, vascularity, and fibrosis compared to controls.
• Peritoneal rest offered no improvement over CG alone.
• Glucocorticosteroid (GC) treatment significantly reduced fibrosis and peritoneal thickness compared to the resting group.
• Azathioprine (AZT) showed no beneficial effects on peritoneal morphology.
• Cyclosporin (CsA) treatment exacerbated fibrosis, vascularity, and inflammation compared to GC therapy.

Conclusions:

• Immunosuppressive therapies, particularly corticosteroid-based regimens, demonstrate therapeutic potential for managing EPS.
• Cyclosporin treatment may pose a risk for developing or worsening EPS due to increased fibrosis and inflammation.